Resumen de Patient profles as an aim to optimize selection in the second line setting: the role of afibercept

Beatriz González Astorga, F. Salvà Ballabrera, Enrique Aranda Aguilar, Elena Élez Fernández, Pilar García Alfonso, E. González Flores, Ruth Vera García, Ana Fernández Montes, Ana María López Muñoz, Antonieta Salud

• Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as frst-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fuorouracil, leucovorin, and irinotecan (FOLFIRI) and fuorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the frst-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from frst line to second line treatment when they develop resistance to frst-line treatment options. It is in this second line setting where Afibercept ofers an alternative and efective therapeutic option, thought its specifc mechanism of action for diferent patient’s profle: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientifc evidence focused on Afibercept as an alternative treatment.